BeyondSpring says U.S. FDA declined to approve neutropenia prevention drug
01/12/2021 13:10
Dec 1 (Reuters) - BeyondSpring BYSI.O said on Wednesday the U.S. Food and Drug Administration had declined to approve its drug candidate, plinabulin, for the prevention of chemotherapy-induced neutropenia, which occurs due to a lower white blood cell count. (Reporting by Amruta Khandekar; Editing by Maju Samuel) ((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value